TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Quality of Life Outcomes in Spinal Cord Stimulation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with neuropathic pain or axial back pain that is not controlled by oral analgesics, opioids, and has failed conservative management.~* Ages 18-90 with no ethnicity or gender predilections.~Exclusion Criteria:~* Patients who have spinal cord injury, multiple stimulator revisions, DRG stimulators, intrathecal pain pumps, complex regional pain syndrome, previous spinal cord stimulator implant, mechanical instability requiring fusion, myelopathy, psychological condition precluding them from complying with therapy, illegal drug abuse including heroin, cocaine, and illegally obtained prescription pills, or have previously been or are currently involved in litigation for medical malpractice.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: None

Study Arms:
- Treatment Group (Type: None): All patients who are considered candidates for spinal cord stimulator implant will be assigned to the Treatment Group. Participiants will be clinically evaluated and given the Owenstry low back disability index, WHODAS 12, Beck depression index and SF-36.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Multicentre Study to Investigate the Performance of the Padd Device in the Assessment of Peripheral Arterial Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~1. Royal Free Hospital - patients \>50 years old referred to the vascular clinic for suspected peripheral arterial disease~2. Leicester~   * age 70 years or older~  * age 50-69 years with a history of smoking, diabetes or peripheral arterial disease~  * 50-69 years with at least two peripheral arterial disease risk factors (hyperlipidaemia, hypertension, family history of cardiovascular disease, previous ischaemic event: myocardial infarction, stroke and TIA)~Exclusion Criteria:~1. bilateral amputation that precludes placement of the Padd sensors on the feet~2. acute deep venous thrombosis, within the previous six months (application of ABPI pressure cuff on legs is not advisable for these patients)~3. skin damage or infection that precludes placement of sensors~4. active psychotic illness or severe cognitive impairment~5. inability to lie supine

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Voyager I: Patient Discharge Using the AB5000 Portable Driver System

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The subject is an AB5000 Circulatory Support System patient (in accordance FDA-approved indications for use) who is suffering acute cardiac dysfunction and is potentially recoverable;~* The subject is male or female, age 18 years or older;~* The subject is able to ambulate unassisted;~* The subject is on stable oral anticoagulation over 7 days (INR 2-4) with no active bleeding;~* The subject is willing and able to read, understand and sign the study specific informed consent form;~* The subject agrees to comply with study protocol requirements, including all follow-up visits and completion of Qol and NIH stroke scale assessments.~Exclusion Criteria:~* The subject, pre-device implant, is qualified as a transplant candidate.~* There is an absence of a trained companion.~* There is an absence of a psycho-social support.~* The subject has an inadequate home environment, such as poor access which may hinder movements.~* The subject has experienced hypotension in last 24 hours based on two consecutive readings spaced by 8 hours with systolic blood pressures \< 90 mmHg.~* The subject requires respiratory assistance.~* The subject has an active infection (positive blood culture and/or body T ≥ 38 degrees C, and/or WBC ≥ 12K/µL).~* The subject requires tube feeding.~* The subject has any other medical condition requiring hospitalization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed diagnosis of biliary tract adenocarcinoma/cholangiocarcinoma~* Must have locally advanced or distant metastatic disease that is not surgically curable~* Failed first-line chemotherapy~* Age ≥ 18 years~* Life expectancy of at least 12 weeks (3 months)~* Performance status 0 or 1~* Adequate liver, kidney, and bone marrow function~Exclusion Criteria:~* Symptomatic metastatic brain or meningeal tumors~* Investigational compound within 4 weeks of enrollment~* History of needing to permanently discontinue prior gemcitabine/ cisplatin regimen for reasons other than progression (i.e. toxicity)~* Any medical condition which, in the investigator's opinion, makes the patient unsuitable for participation~* Pregnant or nursing~* Substance abuse, medical, psychological or social conditions that may interfere with the subject's participation in the study or evaluation of the study results~* Albumin \<2.8~* Uncontrolled or clinically relevant ascites~* Absolute contraindication for MRI imaging such as intracorporeal metal or pacemaker

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RRx-001 the cisplatin and gemcitabine (Type: EXPERIMENTAL): Patients with advanced and metastatic biliary tract adenocarcinoma (cholangiocarcinoma) who had been treated with and failed first-line chemotherapy will be treated with RRx-001 (20 mg) intravenously weekly for up to six weeks followed by retreatment with Gemcitabine 1000 mg/m2 and Cisplatin 25 mg/m2 on Days 1 and 8 of a 21 Day Cycle until tumor progression

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lobectomy and Mediastinal Radiochemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer Responding to Induction Chemotherapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological or cytological diagnosis of non-small cell carcinoma of the lung~* Initially stage III NSCLC~* Pathologically proven N2 or N3 disease~* Any response to induction chemotherapy (whatever the regimen administered)~* Disease still not fully resectable (because of extensive mediastinal N disease) and not suitable for radical radiotherapy (single field) after induction chemotherapy~* Lobectomy possible for the treatment of T disease~* Availability for participating in the detailed follow-up of the protocol~* Informed consent~Exclusion Criteria:~* Prior treatment with radiotherapy or surgery~* Karnofsky PS \< 60~* Functional or anatomical contra-indication to mediastinal radiotherapy~* Functional or anatomical contra-indication to surgical lobectomy~* A history of prior malignant tumour, except non-melanoma skin cancer or in situ carcinoma of the cervix or cured malignant tumour (more than 5 year disease-free interval)~* Malignant pleural or pericardial effusion~* Neutrophils \< 2,000/mm³~* Platelet cells \< 100,000/mm3~* Serum bilirubin \> 1.5 mg/100 ml~* Serum creatinine \> 1.5 mg/100 ml and/or creatinine clearance \< 60 ml/min~* Recent myocardial infarction (less than 3 months prior to date of diagnosis)~* Congestive cardiac failure or cardiac arrhythmia requiring medical treatment~* Uncontrolled infectious disease~* Hearing loss~* Symptomatic polyneuropathy~* Serious medical or psychological factors which may prevent adherence to the treatment schedule

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Lobectomy followed by mediastinal concomitant chemoradiotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Trial of Low-Dose Bevacizumab vs Laser for Type 1 ROP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Birth weight \< 1251 grams~* Newly diagnosed (within 2 days) type 1 ROP in one or both eyes; meeting the following criteria:~  * Zone I, any stage ROP with plus disease, with retinal vessels or ROP in Zone II in any quadrant, or~ * Zone I, stage 3 ROP without plus disease, with retinal vessels or ROP in zone II in any quadrant or~ * Zone II, stage 2 or 3 ROP with plus disease~Exclusion Criteria:~* Previous treatment for ROP~* Stage 4 or 5 ROP in either eye~* All ROP in zone I in either eye (no retinal vessels or ROP extend into zone II in any quadrant)~* Either treatment could not be done within 2 days of diagnosis of type 1 ROP~* Investigator unwilling to randomize or parent unwilling to accept random assignment to either treatment~* Transfer to another hospital not covered by study-certified examiners anticipated within the next 4 weeks~* Active ocular infection or purulent nasolacrimal duct obstruction in either eye~One eye will be excluded, and other eye may be eligible, if either of the following are present:~* Visually significant ocular anomaly (e.g., cataract, coloboma)~* Opacity that precludes an adequate view of the retina

- Gender: ALL
- Minimum Age: None
- Maximum Age: 6 Months
- Healthy Volunteers: f

Study Arms:
- Laser (Type: ACTIVE_COMPARATOR): For infants randomized to laser treatment, it will be given in conjunction with a binocular indirect ophthalmoscope and an appropriate condensing lens, by a study-certified ophthalmologist experienced in the use of this equipment. The treating investigator will be certified as having sufficient experience with laser for ROP, and adequacy of laser treatment will be confirmed by expert review of photographs. Special laser precautions, as mandated by Occupational Safety and Health Administration (OSHA) and facility standards, will be followed.
- Bevacizumab (Type: EXPERIMENTAL): For infants randomized to bevacizumab, the Intravitreous bevacizumab 0.063 mg injection will be given no later than 2 days after the diagnosis of type 1 ROP. The ophthalmologist may choose to give the intravitreous injection in the operating room or at the bedside, with or without anesthesia, after consultation with the attending neonatologist. A binocular indirect ophthalmoscope with an appropriate condensing lens should be available, and the pupils should be dilated.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed mycosis fungoides or Sezary syndrome~  * Stage IB-IVB disease~ * Must have failed at least one prior systemic therapy~ * Generalized erythroderma allowed~* Measurable disease and at least one indicator lesion OR evaluable disease for erythrodermic patients only~  * Prior radiotherapy to areas of measurable disease allowed if disease progression is present in the site or if measurable disease is present outside irradiation port~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* ECOG 0-2 OR~* WHO 0-2~Life expectancy:~* At least 3 months~Hematopoietic:~* WBC at least 3,000/mm\^3~* Absolute granulocyte count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than 2.2 mg/dL~* SGOT or SGPT no greater than 2 times upper limit of normal (ULN)~* Alkaline phosphatase no greater than 2 times ULN~Renal:~* Creatinine no greater than 2.0 mg/dL~Cardiovascular:~* No New York Heart Association class III or IV heart disease~* No clinically significant peripheral venous insufficiency~Other:~* HIV negative~* No poorly controlled diabetes mellitus~* No acute infection requiring IV antibiotics~* No other medical condition that would prevent ingestion or absorption of oral medication~* No other neoplasm within the past 5 years except curatively treated squamous cell or basal cell skin cancer, melanoma in situ, or carcinoma in situ of the cervix~* Not pregnant or nursing~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior biologic therapy and recovered~* No concurrent growth factors or epoetin alfa~Chemotherapy:~* At least 4 weeks since prior chemotherapy and recovered~Endocrine therapy:~* At least 4 weeks since prior topical steroids~Radiotherapy:~* See Disease Characteristics~* At least 2 weeks since prior radiotherapy for local control or palliation and recovered~Surgery:~* Recovered from prior major surgery~Other:~* No other concurrent investigational drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cryobiopsy Versus Forceps Biopsy for Pulmonary Lesions

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \>/= 18~2. At least one peripheral lung lesion \>8mm documented on CT scan referred for diagnostic bronchoscopy~3. Subject is able to undergo informed consent~Exclusion Criteria:~1. Coagulopathy (platelet count \< 50,000, INR \> 1.5) detected on blood testing done within 6 weeks of the procedural visit~2. Lesion associated with a prominent vessel evident on CT scan~3. Pure ground glass lesion~4. Fibrotic interstitial lung abnormalities on chest CT~5. Bullous emphysema in region of nodule~6. Supplemental oxygen utilization at baseline~7. BMI \> 40~8. End stage renal disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single intervention arm - transbronchial biopsy (Type: EXPERIMENTAL): Patients enrolled in this single arm study will have lung nodules biopsied by traditional forceps followed by transbronchial cryobiopsy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Sensitivity and Specificity of Aridol Challenge for a Diagnosis of Asthma by a Specialist Pulmonologist

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Informed consent~* Provisional or possible asthma diagnosis~* FEV1 at least 70% of predicted at inclusion~Exclusion Criteria:~* Contraindications for bronchial provocation challenge or spirometry~* Respiratory tract infection within previous 6 weeks~* Significant co-morbidity~* \> 10 pack year smoking history~* Other lung diseases~* Pregnancy, lactation

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Rosuvastatin on Endothelial Function

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* HIV infection~* Age \> 18 years old~* On stable antiretroviral therapy for \> 6 months with no plans to change therapy during the treatment phase of the study~* Plasma HIV RNA \< 50 copies/mL~* Karnofsky performance score \> 70 within 30 days prior to study entry~* Ability to understand and sign informed consent~* Following laboratory values obtained within 30 days prior to randomization:~  * Absolute neutrophil count (ANC) \> 750/mm3~ * Hemoglobin \>/= 8.0 g/dL~ * Platelets \>/= 50,000/mm3~ * ALT (SGPT) and AST (SGOT) \< 2.5 x ULN~ * Fasting glucose \< 126 mg/dL~ * TSH \< 3.0 mIU/L~* HDL-C \< 50 mg/dL in men, \< 55 mg/dL in women~* Direct LDL-C \</= 130 mg/dL~* Calculated creatinine clearance \> 50 mL/min~* Willing to be treated with rosuvastatin or be on an observational arm for a minimum of 3 months~* Female subject must not participate in a conception process (active attempt to become pregnant) or be post-menopausal. If participating in sexual activity that could lead to pregnancy, the subject must use contraception while receiving study medication and 30 days after stopping the medication~Exclusion criteria~* History of past cardiovascular event~* Acute illnesses or active AIDS-defining opportunistic infection (OI) within 30 days prior to entry~* Other chronic illness including diabetes, autoimmune diseases, and endocrinopathies~* Serology positive for hepatitis B surface antigen or hepatitis C antibody~* Signs and symptoms of liver failure~* Receipt of supraphysiologic glucocorticoid therapy within 3 months prior to study entry~* Use of lipid lowering agents within 30 days prior to study entry~* Receipt of an HIV vaccine or investigational agents~* Pregnancy or breast-feeding~* Presence of any active malignancy within the last 5 years~* Severe Hypertension (Systolic \>/= 180 or Diastolic \>/= 110 mm Hg)~* Use of oral postmenopausal hormone replacement therapy~* Known hypersensitivity to rosuvastatin~* Active drug or alcohol dependence~* Any acute illness within 30 days prior to study entry that, in the opinion of the site investigator, would interfere with participation in the study.~* Use of lopinavir/ritonavir (Kaletra) as part of current HIV antiretroviral regimen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- rosuvastatin (Type: EXPERIMENTAL): rosuvastatin 10 mg qd increased to 20 mg qd as tolerated

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Image Quality of EOSedge for Radiographic Evaluation of Hip Implant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient 18 years of age or older~* Came to the imaging department to perform a preoperative assessment for hip replacement or revision~Exclusion Criteria:~* Patient under guardianship or curatorship~* Patient participating in an interventional study~* Patient unable to read and/or write

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EOSedge imaging (Type: OTHER): Single arm study : All subjects include in the study underwent micro-dose EOS x-ray and digital radiography for radiographic evaluation of hip implant

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression Assays

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Subjects with histologically confirmed stage II and III rectal adenocarcinoma or subjects with histologically confirmed stage II and III anal SCC~2. Subjects greater than 18 years of age.~3. Subjects who will undergo prescribed neoadjuvant chemotherapy and/or radiotherapy and have surgical resection prior to further treatment or pathologic confirmation of treatment response using endoscopy or ultrasound.~4. Subjects with:~   * twenty (20) unstained sections on charged slides available from tumor block (FFPE) used for the diagnosis of rectal/anal carcinoma or adjacent to this block (pre-neoadjuvant biopsy sample); and~  * four (4) unstained slides available from post-chemoradiation surgery to allow for blinded pathology review and assessment of pathCR, partial CR, or exCTRT. Slides from surgical resection are not necessary in cases with documented post-surgical determination of response by ultrasound or endoscopy.~5. Subjects willing to complete study follow up for outcomes.~6. Subjects from who informed consent can be obtained.~Exclusion Criteria:~1. Subjects with carcinoma in situ or Stage I rectal/anal carcinoma.~2. Subjects with Stage IV rectal/anal carcinoma.~3. Subjects with diagnosis of other malignant tumors with the exception of non-melanoma skin cancers cured by resection only.~4. Subjects that have received prior chest or upper abdomen radiotherapy and/or system chemotherapy within the past 5 years~5. Subjects who are unwilling to complete study follow up~6. Employees and family members of Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy